DUBLIN–(BUSINESS WIRE)–The “Global Stem Cells Market: Focus on Clinical Therapies, 2020 – 2030” report has been added to ResearchAndMarkets.com’s offering.
This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
According to the WHO, in 2020, nearly 75% of fatalities that are estimated to be reported across the globe, are likely to be caused due to diseases, such as chronic stroke disease, diabetes, cancer, heart disease, and certain mental health conditions. In addition, as per a report published by the Center for Managing Chronic Disease, University of Michigan, more than 50% of the global population was estimated to be living with some form of chronic illness.
The rising prevalence of these clinical conditions has resulted in dire need for the identification of effective therapeutic options. Despite advances in healthcare, there is an evident lack of permanent treatment solutions for many aforementioned diseases. Majority of the currently available treatment options focus on palliative care and are incapable of addressing the root cause of disease, therefore, are unable to improve quality of life of patients.
Since the first bone marrow transplant in 1950s, these regenerative cellular therapies have garnered significant attention within the biopharmaceutical industry. Over the years, advances in the field of cell biology and regenerative medicine have led to the development of a number of stem cell therapies, which are believed to possess the potential to address several unmet needs related to the treatment of a wide range of disease conditions. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, curing affiliated disease symptoms.
In fact, such interventions have also been shown to enable cell regeneration, restoring normal functioning capabilities in affected organs. Till date, nearly 25 stem cell-based therapies have been approved; popular examples include EYE-01M (2019), Alofisel (2018), MACI (2016), Stempeucel (2016) and Strimvelis (2016). Further, several such therapies are presently being evaluated across 540 active clinical trials worldwide.
This emerging field of research has received significant capital investments from several big pharma companies and venture capital funds / investors. Despite the associated optimism, the growth of this market is stunted by a number of development and manufacturing related challenges, primarily revolving around the limited availability of the required expertise and infrastructure to produce such products. However, the availability of innovative technology platforms, large target patient population, encouraging clinical trial results, and extensive government support, the stem cell therapies market is poised to grow in the long-term.
The report features detailed transcripts of interviews held with the following industry stakeholders:
- William L Rust (Founder and Chief Executive Officer, Seraxis)
- Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)
- Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
- Kikuo Yasui (Director and Chief Operating Officer, Heartseed)
- Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)
- Gilles Devillers (President, Bio Elpida)
- Fiona Bellot (Business Development Manager, Roslin Cell Therapies)
- David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
- Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
- Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY PROFILES
6. KEY THERAPEUTIC AREAS
7. ANSOFF MATRIX EVALUATION
8. ACADEMIC GRANTS ANALYSIS
9. CLINICAL TRIAL ANALYSIS
10. STEM CELL MANUFACTURING MARKET LANDSCAPE AND KPIs FOR EVALUATING CONTRACT SERVICES PARTNERS
11. STEM CELL THERAPY DEVELOPERS AND CMOs: OPPORTUNITY ASSESSMENT
12. KEY COMMERCIALIZATION STRATEGIES
13. MARKET FORECAST
14. CONCLUSION
Companies Mentioned
- 3P Biopharmaceuticals
- AA Partners
- AbbVie
- Aegle Therapeutics
- AGC
- Albert Einstein College of Medicine
- Allele Biotechnology & Pharmaceuticals
- Altaco XXI
- American CryoStem
- Amgen
- Andalusian Initiative for Advanced Therapies
- Angel Biotechnology
- Angiocrine Bioscience
- Anterogen
- apceth Biopharma
- Aspire Health Science
- Astellas Pharma
- Athersys
- Atlantic Bio GMP
- Augusta University
- Axis Biotec Brasil
- Azidus Brasil
- Baylor College of Medicine
- Baylx
- Beckman Research Institute
- BHI Therapeutic Sciences
- Bio Elpida
- BioCardia
- BioGenCell
- Bioinova
- BioNTech IMFS
- Bioquark
- BioRestorative Therapies
- bluebird bio
- Bone Therapeutics
- BrainStorm Cell Therapeutics
- Brigham And Women’s Hospital
- Bukwang Pharmaceutical
- Caladrius Biosciences
- Capricor Therapeutics
- CAR-T (Shanghai) Biotechnology
- Case Western Reserve University
- Cedars-Sinai Medical Center
- Celgene
-
And Many Many More!
For more information about this report visit https://www.researchandmarkets.com/r/lir211
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900